Comparative Pharmacology
Head-to-head clinical analysis: SULPHRIN versus TRIPLE SULFAS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULPHRIN versus TRIPLE SULFAS.
SULPHRIN vs TRIPLE SULFAS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Its active sulfide metabolite is responsible for therapeutic effects.
Competitive inhibition of dihydropteroate synthase, thereby blocking folate synthesis and bacterial DNA replication. Triple sulfas (sulfadiazine, sulfamerazine, sulfamethazine) act synergistically to inhibit folic acid synthesis.
1-2 tablets (500-1000 mg paracetamol, 65-130 mg caffeine) orally every 4-6 hours as needed, not exceeding 8 tablets (4000 mg paracetamol) per day for adults.
1 to 2 tablets (each containing sulfadiazine 167 mg, sulfamerazine 167 mg, sulfamethazine 167 mg) orally every 4 hours initially, then 2 tablets every 6 hours. Maximum daily dose: 6 grams of total sulfonamide.
None Documented
None Documented
2-3 hours; clinically, hepatic impairment may prolong to 5-10 hours requiring dose adjustment
Terminal elimination half-life ranges from 10-12 hours in adults with normal renal function. Prolonged in renal impairment (up to 24-48 hours) and neonates (40-120 hours).
Renal: 85-90% as glucuronide and sulfate conjugates, 5-10% unchanged; biliary/fecal: <5%
Primarily renal; approximately 70-100% excreted unchanged in urine via glomerular filtration and tubular secretion. Minor biliary/fecal elimination (<5%) with enterohepatic circulation possible.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic